Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on peginterferon alfa in multidrug-resistant chronic hepatitis B after long-term tenofovir-based salvage therapy
ACTRN12613000946718Phase 2Not yet recruiting
- Sponsor
- Peter Angus
- Start
- Oct 2013
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegylated interferon alpha, tenofovir disoproxil fumarate and lamivudine in Chronic Hepatitis B (CHB) and Multidrug-resistant chronic hepatitis B (2 arms), sponsored by Peter Angus. Primary endpoint: Change in HBsAg titre during antiviral therapy. Planned start Oct 2013; status: not yet recruiting.
02
Drugs
pegylated interferon alphatenofovir disoproxil fumaratelamivudine
03
Conditions
Chronic Hepatitis B (CHB)Multidrug-resistant chronic hepatitis B
Beyond the preview
Go deeper on ACTRN12613000946718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000946718.